Early access
Sign in
Taking people in United KingdomNo phase

Studying fat around the heart in people with heart failure

Compares fat around the heart with heart function in adults with heart failure.

Key facts

Who runs it
University of Leicester
Where
Leicester, United KingdomSee the site
Trial code
Registry title
The Role of Epicardial Adiposity in Heart Failure With Preserved Ejection Fraction
Status
Recruiting
People taking part
130 people, planned
Started
12 Feb 2025
Expected to end
Aug 2037
Type of study
Observational
Record updated
30 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with heart failure with preserved ejection fraction (HFpEF), both with and without obesity. They will have CT and MRI scans and blood tests.

Age
18 years or older
Sex
All sexes can join
Disease stage
Heart failure with preserved ejection fraction (HFpEF), diagnosed by an experienced cardiologist, or signs and symptoms of heart failure with a HFA-PEFF score ≥5

Main reasons for not taking part

  • LV ejection fraction <45%
  • Severe primary valvular heart disease
  • Heart failure due to infiltrative, hypertrophic, restrictive or congenital heart disease
  • Contraindications to cardiac CT or MRI, including eGFR ≤30ml/min/1.73m2, or an MRI-incompatible device
  • Pregnant women

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Participant is willing and able to give informed consent for participation in the study
  • Aged ≥18 years old
  • Diagnosed with HFpEF by an experienced cardiologist or signs and symptoms of heart failure with a HFA-PEFF score ≥5
  • Able to understand written English

Who cannot take part

  • Severe primary valvular heart disease
  • HFpEF due to infiltrative cardiomyopathy (cardiac amyloidosis or sarcoidosis), genetic hypertrophic cardiomyopathy, restrictive cardiomyopathy/pericardial disease or congenital heart disease
  • Known heritable, idiopathic or drug-induced pulmonary arterial hypertension
  • LV ejection fraction <45%
  • Recovered ejection fraction (previous ejection fraction <40%) unless reduced ejection fraction was in context of tachycardia induced cardiomyopathy (eg atrial fibrillation/atrial flutter)
  • Absolute contraindications to cardiac CT or MRI including estimated glomerular filtration rate (eGFR) ≤30ml/min/1.73m2. Patients with MRI-compatible devices are be excluded
  • Women who are pregnant

Where in United Kingdom

  • Glenfield Hospital, University Hospitals of LeicesterLeicester, United KingdomContact: Sarah L Ayton, MBBSTaking people

About the trial

What the trial wants to find out

In this study the investigators are aiming to recruit 130 patients with heart failure with preserved ejection fraction who are obese and non-obese to undergo CT and MRI scans, as well as some other investigations including blood tests, to help investigate if having more fat around the heart leads to worse heart function in this condition. This may lead to the development of new treatments aimed at lowering fat levels around the heart and in the rest of the body, specifically to treat HFpEF.

The group in the trial

  • Participants with HFpEF

    Obese and non-obese participants with heart failure with preserved ejection fraction

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
The Role of Epicardial Adiposity in Heart Failure With Preserved Ejection Fraction
Plain-language title
Studying fat around the heart in people with heart failureGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
30 April 2026